Ionis Pharmaceuticals (IONS) and its Japanese partner, Otsuka Pharmaceutical (OTSKY), said on Wednesday that the European Commission has approved their RNA-targeted medicine, Dawnzera, as a treatment ...

Wendy Wisner is a journalist and international board certified lactation consultant (IBCLC). She has written about all things pregnancy, maternal/child health ...

While all cases of hereditary angioedema (HAE) should be managed by HAE specialists, optimal management requires a multidisciplinary team of collaborating physicians and other personnel, including ...

Angioedema is deep tissue swelling under the skin. It may affect various parts of the body, including the hands. Angioedema may cause visible swelling on one or both of your hands. It might happen on ...

Hereditary angioedema (HAE) is a genetic condition that causes bouts of swelling in the tissue under your skin. The uncomfortable swelling can happen in many different parts of your body, including ...

Angioedema is deep swelling that occurs when fluid builds up under your skin or mucus membranes. It may affect your face, throat, gastrointestinal tract, or other parts of your body. Angioedema may ...

Dawnzera (donidalorsen) is a medicine used to prevent attacks of hereditary angioedema (HAE). HAE is a rare genetic condition that is caused by a problem with a gene that makes a blood protein called ...

Pharvaris, a biopharmaceutical company based in Zug, Switzerland, announced that abstracts for multiple presentations have been accepted for the 2025 National Summit of the US Hereditary Angioedema ...

The FDA has approved Andembry (garadacimab), a once-monthly injection, to prevent swelling attacks in people with hereditary angioedema (HAE). Hereditary angioedema is a rare disorder that causes ...

Andembry (garadacimab) can help people with hereditary angioedema prevent potentially serious swelling attacks. The FDA has approved Andembry (garadacimab), a once-monthly injection, to prevent ...

Garadacimab-gxii is the first FDA-approved factor XIIa inhibitor for hereditary angioedema, offering a once-monthly prophylactic treatment option. The VANGUARD trial showed an 87% reduction in HAE ...